



Receipt date: 09/23/2004

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/642,974
				Filing Date	08-18-2003
				First Named Inventor	MICHAELIS
				Group Art Unit	1616
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	DEAV2002/0064 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/B.K./		HOTTELET, et al., Development of Ikb Kinase Inhibitors As Anti-Inflammatory Therapeutics, Inflammation Research Supplemental, page 2, (2000), S91, XP009023847	
/B.K./		YIN, et al., The Anti-Inflammatory Agents Aspirin And Salicylate Inhibit The Activity of Ikb Kinase-Beta, Nature, MacMillan Journals Ltd. Vol. 39615, Pages 77-80, (1998), XP002938591	

Examiner Signature	/Brian-Yong Kwon/	Date Considered	07/31/2008
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.K./